Study shows Pfizer booster can be given along pneumonia shot

The study aimed to determine the combination's safety and immune response after the pneumonia vaccine.



Pfizer said on Wednesday that booster doses of its COVID-19 vaccine can be given with its pneumonia vaccine and that a late-stage study found strong safety and immune responses in adults aged 65 and up. In 570 participants, the company's next-generation pneumococcal conjugate vaccine, PREVNAR 20, with a third dose of the Pfizer-BioNTech COVID-19 shot was tested in a study that began in May last year. The aim of the study was to test the safety of the combination and the immune response after adding the pneumonia vaccine to the existing COVID-19 vaccine. PREVNAR 20 and the COVID-19 booster dose produced similar responses when administered jointly or with placebo, according to the pharmaceutical company.


According to Pfizer, the data supports the possibility of administering PREVNAR 20 and the company's COVID-19 vaccine at the same time, lowering the number of visits people need to make to doctors or pharmacies for recommended vaccination. The US Food and Drug Administration approved PREVNAR 20 in June of last year to help protect adults against most invasive pneumococcal infections and pneumonia. The Pneumonia vaccine helps protect against 20 streptococcus pneumoniae (pneumococcus) serotypes. Participants were chosen from the companies' late-stage COVID-19 vaccine study, as well as those who had received the second dose of the COVID-19 vaccine at least six months prior to enrolling in the co-administration study. Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.